Clinical trials: Chronic Hepatitis D
Hepatitis D
Pegylated Interferon to Treat Chronic Hepatitis D
This study will evaluate the safety and effectiveness of a long-acting form of alpha interferon called pegylated interferon in treating hepatitis D virus (HDV) infection.
- Trial name
- NCT00023322
- Testing
- Peginterferon Alpha-2a
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis D
Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA
This observational study will be conducted in patients with chronic co-infection with hepatitis B and D viruses, with negative PCR for HDV RNA in peripheral blood and no signs of active liver inflammation according to blood…
- Trial name
- NCT06121427
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Center of target therapy
Chronic Hepatitis D Infection
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.
- Trial name
- NCT07762027
- Testing
- ABI-6250
- Where
- 22 sites in France, Georgia and 9 more
- Volunteers
- 80 people
- Sponsor
- Assembly Biosciences
Chronic Hepatitis D Infection
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta…
- Trial name
- NCT02637999
- Testing
- PEG IFN alfa-2a, Myrcludex B
- Volunteers
- 24 people
- Sponsor
- Hepatera Ltd.
Hepatitis D, Chronic, Hepatitis B Chronic Infection
Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With Chronic Hepatitis D Infection
Hepatitis D virus (HDV) is a major global health issue, with an estimated 12 million people living with the infection worldwide.
- Trial name
- NCT07610772
- Testing
- HepB mAb19
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 15 people
- Sponsor
- Aarhus University Hospital
Parathyroid Hormone, Tenofovir Disoproxil Fumarate
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF
Nucleot(s)ide is an antiviral drug that can reduce the number of viruses, reduce the risk of HCC, regress hepatic fibrosis and reduce death from Hepatitis B viral infection.
- Conditions
- Parathyroid Hormone, Tenofovir Disoproxil Fumarate, Chronic Hepatitis B Virus, Vitamin D
- Trial name
- TDF (NCT05313477)
- Testing
- Ergocalciferol Capsules, Calcium carbonate
- Where
- Thailand
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Hepatitis D, Chronic
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D.
- Trial name
- NCT01088659
- Testing
- peginterferon alfa-2a [Pegasys], tenofovir
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Hepatitis D, Chronic
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200 mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic…
- Trial name
- LOWR6 (NCT05229991)
- Testing
- Lonafarnib, Ritonavir
- Where
- 3 sites in Israel, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- Soroka University Medical Center
Hepatitis D, Chronic
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen compared to NA alone.
- Trial name
- REEF-D (NCT04535544)
- Testing
- JNJ-73763989, Entecavir (ETV) monohydrate, Tenofovir disoproxil
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 52 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis D
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
Randomized, double blind study comparing the efficacy of pegylated interferon-alfa2a plus placebo versus pegylated interferon-alfa2a plus tenofovir for the treatment of chronic delta hepatitis.
- Trial name
- HIDIT-II (NCT00932971)
- Testing
- PEG-IFN alfa-2a, Tenofovir
- Where
- 10 sites in Germany, Greece and 1 more
- Volunteers
- 70 people
- Sponsor
- HepNet Study House, German Liverfoundation
Hepatitis B Virus
The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
Abstract Telbivudine is a potent inhibitor of HBV but, due to a low genetic barrier to resistance, a high incidence of resistance has been observed in patients with high baseline levels of replication and in those with detectable…
- Trial name
- NCT01083251
- Testing
- Peginterferon + Vitamin D, Peginterferon, Sebivo
- Where
- 2 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Ziv Hospital
Chronic Hepatitis Delta
Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
Background: Chronic hepatitis D is a serious liver disease caused by a virus. Currently, no medications are approved to treat chronic hepatitis D. Objective: To test a combination of 3 drugs in people with chronic hepatitis D.
- Trial name
- NCT05953545
- Testing
- Peginterferon Lambda
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis D Infection
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.
- Trial name
- NCT06907290
- Testing
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Where
- 30 sites in United States, Australia and 9 more
- Volunteers
- 150 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Chronic Hepatitis Delta Virus Infection
Expanded Access for Bulevirtide
The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).
- Trial name
- NCT06780579
- Testing
- Bulevirtide
- Sponsor
- Gilead Sciences
Hepatitis D, Chronic
An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)
This prospective, multicenter, observational study will assess the prevalence of chronic hepatitis D in patients with chronic hepatitis B in Romania and evaluate the efficacy of Pegasys (peginterferon alfa-2a) in patients with…
- Trial name
- NCT01861444
- Where
- Romania
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis D
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Multicenter pharmacological observational prospective, no-profit, study. This study was designed to get a "real-life" snapshot across several Italian Hepatology centers.
- Trial name
- D-SHIELD (NCT06122285)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Hepatitis C
Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers
The objective of this study is to assess the prevalence of vitamin D deficiency in patients with chronic Hepatitis C compared to a matched control group of healthy individuals in the Sioux Falls area.
- Trial name
- NCT01274013
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Avera McKennan Hospital & University Health Center
Hepatitis D
Lonafarnib for Chronic Hepatitis D
Background: Chronic hepatitis D is a severe disease of the liver caused by infection with the hepatitis D virus. The hepatitis D virus can only infect a person who also has hepatitis B; therefore, people with delta hepatitis have…
- Trial name
- NCT01495585
- Testing
- Lonafarnib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Chronic
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression
This open-label, single-arm, multicenter study will evaluate the efficacy and safety of adding Pegasys (peginterferon alfa-2a) to nucleos(t)ide analogue (NAs) treatment in participants with HBeAg-negative chronic hepatitis B…
- Trial name
- NCT01706575
- Testing
- Pegylated Interferon (Peginterferon) Alfa-2a, Nucleos(t)ide Analogues (NA)
- Where
- 27 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B, Chronic Hepatitis D
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize that pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV) may be effective in the treatment of chronic hepatitis D…
- Trial name
- NCT00117533
- Testing
- pegylated IFN alfa-2b plus ribavirin
- Where
- 2 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital